Feel Therapeutics, the Digital Precision Medicine company for mental and behavioral health, announced today that Michel Vounatsos, former CEO of Biogen, has joined as a Chairman of their Advisory Board. Additionally, Feel has secured new funding from Satori Neuro, Metavallon VC, and existing investors such as SOSV, SeedtoB, and others, to fuel its expansion plans. Along with the new funding, Amy Kruse, Chief Investment Officer of Satori Neuro, a pioneering fund focused on mental health, neurotechnology, and human flourishing, has joined the Board of Directors as an observer. These new investors join Feel's existing group of investors, which includes Felicis, SOSV, Anthemis, SeedtoB, and others, that continue to support the company.

Feel Therapeutics is developing digital biomarkers and therapeutics to bring objective data and measurement to the way we diagnose, manage, and care for mental health. Their mental health solutions include Feel Relief, a monthly digital subscription to reduce stress, promote sleep, and improve emotional wellbeing, Feel Program, a mental health patient support program combined with remote health monitoring, and Feel DTx, the world's first data-driven digital therapeutic to treat patients with Major Depressive Disorder (MDD) and/or Generalized Anxiety Disorder (GAD) through digital cognitive behavioral therapy (CBT), a health coach, and on-time interventions to deliver 24/7/365 mental health support to those at their point of need.